GSK Q3 preview: Analysts project solid quarter; cost-saving progress in focus

What happened

GSK will report third-quarter earnings on October 28 before markets open. Revenue is expected to rise 38% from a year earlier to $11.81 billion. Last quarter GSK announced a three-year plan to cut annual spending by £1.9 billion ($2.5 billion).

Confirmed

Global impact / market context

The savings plan is meant to free up money for late-stage drug research, which means funding the next generation of medicines. Cutting up to 1,217 jobs in Belgium lowers costs but can disrupt operations, so investors want proof the savings arrive without hurting revenue growth.

Analyst inference

Analysts have recently lowered profit and revenue estimates, so expectations are cautious going into the report. GSK has beaten revenue estimates 88% of the time over two years, which sets a higher bar. Guidance for the fourth quarter and full year will shape how investors judge the reset.

Analyst inference

What to watch

1. GSK's £400 million ($531.1 million) three-year investment in Britain includes a new 300,000-square-foot research facility in Cambridge focused on cancer and respiratory medicines. Confirmed
2. Management may give forward-looking indications on how the cost-saving program and strategy reset will affect future spending, research funding, and profit. Proposed
3. Updates on the up to 1,217 planned job cuts in Belgium could show whether restructuring costs and savings are arriving on schedule and within budget. Analyst inference

Evidence

• seekingalpha.com